Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Top Treatments for High Cholesterol

Page 1 of 2

About a third of American adults have high LDL cholesterol — that’s the bad kind — but less than half of adults with high LDL seek treatment, according to the Centers for Disease Control and Prevention.

I smell an investment opportunity.

Merck & Co., Inc. (NYSE:MRK)

There’s just one problem: Generics abound
While there’s an opportunity to increase the market for cholesterol drugs, it’s likely going to come from generic drugs. Both Merck & Co., Inc. (NYSE:MRK)‘s Zocor and Pfizer Inc. (NYSE:PFE)‘s Lipitor are available as cheap generics.

Sure, the generic-drug companies could benefit from increasing demand, but the products are just a small portion of their overall revenue. Buying for their copycat versions of Zetia and Lipitor isn’t exactly an investment thesis.

AstraZeneca plc (ADR) (NYSE:AZN)‘s Crestor, which is in the same class as Zocor and Lipitor, is still under patent protection, but having to compete with generics is putting pressure on sales. Pfizer Inc. (NYSE:PFE) had the same issue with U.S. sales of Lipitor when generic versions of Zocor were introduced. Crestor will remain a megablockbuster for some time, but I wouldn’t buy AstraZeneca for it.

That leaves Merck & Co., Inc. (NYSE:MRK)‘s Zetia, which works to lower cholesterol through a different mechanism. In fact, Zetia has been combined with Zocor to form Vytorin, and with Lipitor to create Liptruzet. The three pills have a good shot at substantial growth, but only after the readout of the Improve-It trial, which is testing Vytorin against Zocor to see if adding Zetia not only reduces cholesterol further but also decreases heart-related events such as heart attacks and strokes.

The trial is scheduled to finish up in September 2014. The Zetia franchise made up 9.6% of Merck & Co., Inc. (NYSE:MRK)’s sales in the first quarter, so it could have major implications on Merck’s stock price in either direction.

In the works
PCSK9 is the newest target that seemingly every company is going after.

Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have one that’s codenamed REGN727/SAR236553. In a phase 2 trial, it reduced bad LDL cholesterol by up to 67.9% compared with a 10.7% reduction in patients receiving placebo.

Amgen, Inc. (NASDAQ:AMGN)‘s PCSK9 inhibitor called AMG 145 seems to have comparable efficacy, reducing bad cholesterol by up to 66% in patients already taking a statin.

Pfizer Inc. (NYSE:PFE), Roche, and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) also have drugs targeting PCSK9.

There’s obviously lots of competition, and the data are a little too early to pick a winner yet. We’ll have to wait for a phase 3 data to figure out which drug works the best.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

The 10 Most Expensive Cruise Ships in the World

The 10 Fastest Supercomputers in the World

The 10 Best Countries for Doing Business 2015

6 Most Expensive Fruits In The World

10 Worst Airlines in the World

The 10 Biggest Tax Havens in the World to Stash Your Money

The 15 Most Murderous Countries in the World

10 Largest Colleges in the World: Bigger Isn’t Always Better

Comedians in Cars Getting Coffee: The 6 Comedians Seinfeld Needs to Interview

Easy Money: The 10 Most Successful Investors in the World Today

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!